![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Tracking Information | |
---|---|
First Received Date † | September 13, 2004 |
Last Updated Date | December 19, 2006 |
Start Date † | March 2003 |
Current Primary Outcome Measures † | |
Original Primary Outcome Measures † | |
Change History | Complete list of historical versions of study NCT00091624 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures † | |
Original Secondary Outcome Measures † | |
Descriptive Information | |
Brief Title † | A Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) |
Official Title † | A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) |
Brief Summary | A Phase I Study of CC-5013 in combination with Doxil, Vincristine and Decadron (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma |
Detailed Description | |
Study Phase | Phase I |
Study Type † | Interventional |
Study Design † | Treatment, Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety Study |
Condition † | Multiple Myeloma |
Intervention † | Drug: CC-5013 |
Study Arms / Comparison Groups | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|
Recruitment Information | |
Recruitment Status † | Active, not recruiting |
Enrollment † | 40 |
Completion Date | December 2005 |
Primary Completion Date | |
Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
Gender | Both |
Ages | 18 Years and older |
Accepts Healthy Volunteers | No |
Contacts †† | |
Location Countries † | United States |
Expanded Access Status | |
Administrative Information | |
NCT ID † | NCT00091624 |
Responsible Party | |
Secondary IDs †† | |
Study Sponsor † | Celgene Corporation |
Collaborators †† | |
Investigators † | |
Information Provided By | Celgene Corporation |
Verification Date | December 2006 |
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |